Welcome to our dedicated page for Sinovac Biotech SEC filings (Ticker: SVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sinovac Biotech Ltd. filings document the company’s foreign private issuer reporting for a China-based vaccine developer, including Form 20-F annual reporting and Form 6-K current reports. The disclosures cover vaccine operations, consolidated financial statements, interim results, product portfolio context and pipeline categories such as combination vaccines, recombinant protein vaccines, mRNA technologies and antibodies.
Recent filings also record auditor engagement and annual-report correction matters, Nasdaq listing-compliance notices tied to filing deadlines, and board governance actions, including director independence, committee appointments and proceedings over board composition. These filings frame Sinovac’s capital-market reporting, governance controls and regulatory status as a Nasdaq issuer.
Sinovac Biotech Ltd. reported that it has regained full compliance with the Nasdaq Global Market’s listing requirements. Nasdaq’s Hearing Advisor notified the company in a letter dated June 10, 2026, confirming compliance with Listing Rule 5250(c)(1) after Sinovac filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026.
The company will remain under a Mandatory Panel Monitor under Listing Rule 5815(d)(4)(B) until May 20, 2027, as previously determined by the Nasdaq Hearing Panel. The hearing that Sinovac had applied for has been canceled following the compliance determination.
Sinovac Biotech reported audited 2025 results showing modest revenue growth but a sharp swing to loss. Sales rose to $386.0 million from $361.4 million, driven by overseas markets where revenue reached $124.8 million, up 93.9% and lifting the international share of sales to 32.3%.
Gross margin improved from 61.1% to 67.9% as higher-margin export vaccines, including varicella and influenza, gained traction and cost controls took hold. However, heavy expenses, a large $202.8 million impairment on PP&E, intangibles and goodwill, and lower investment income pushed 2025 to a $198.8 million net loss, versus $40.7 million income in 2024.
Cash and restricted cash rose to $1.2 billion at year-end, mainly from maturing investments, even as operating activities used $512.2 million and the company paid a special cash dividend totaling $3,958.2 million. Management highlighted strong overseas momentum and an advancing late-stage vaccine pipeline, including multiple Phase III candidates.
Sinovac Biotech Ltd. files its annual Form 20-F as a China-focused vaccine maker whose fortunes have swung with COVID demand and heavy R&D spending. Revenue fell from $1.5 billion in 2022 to $470.2 million in 2023 after suspending CoronaVac production.
The company is reinvesting and returning large amounts of cash. It reported $216.2 million of 2025 R&D, equal to 56.0% of revenue, and held $1,156.4 million in cash and restricted cash as of December 31, 2025. In 2025, Sinovac Hong Kong upstreamed $3,958.2 million in dividends to the Antigua parent, which in turn declared a special cash dividend of $55.00 per common share.
Management highlights structural risks from operating through mainland Chinese subsidiaries, including licensing and foreign-exchange rules that govern cash movement, new CSRC filing requirements for future overseas offerings, evolving cybersecurity and data rules, and potential U.S. trading bans under the HFCAA if PCAOB access to China-based auditors is curtailed again. The report also flags declining birth rates in China and stronger price competition, which are pressuring demand and margins for pediatric and influenza vaccines.
Sinovac Biotech Ltd. reports that Nasdaq notified the company it had regained compliance with periodic filing and interim financial requirements as of May 8, 2026, after timely filing its 2024 Form 20-F and a mid-2025 Form 6-K as required.
The same update explains that Nasdaq later issued a Staff Determination on May 22, 2026 because Sinovac did not timely file its Form 20-F for the year ended December 31, 2025. Under a one-year panel monitoring period, this noncompliance could lead to suspension and delisting.
Sinovac has requested a hearing before the Nasdaq panel and an additional stay, which automatically pauses any suspension of its securities for 22 calendar days from the Staff Determination while the hearing process moves forward.
Sinovac Biotech Ltd. is extending the deadline for shareholders and nominee brokers to submit payment instructions for its previously declared special cash dividend of US$55.00 per common share. The dividend is payable to valid holders of common shares as of the close of business on May 23, 2025.
The original instruction submission deadline of December 31, 2025 has been pushed back to June 30, 2026, giving eligible holders more time to complete the required materials so they can receive the dividend.
Sinovac Biotech reported first-half 2025 sales of $130.3 million, slightly above $128.7 million a year earlier, with overseas sales rising 29.4% and offsetting weaker demand in the Chinese Mainland. Gross profit increased to $81.5 million, lifting margin to 62.5% from 54.0% as inventory provisions fell.
Operating expenses remained heavy, including $69.9 million of losses on disposal and impairment of property, plant and equipment, in-process R&D and goodwill tied to a rabies vaccine subsidiary. Other income, net dropped to $161.9 million from $294.6 million as investment income declined, driving a net loss of $96.6 million versus prior net income of $59.0 million. Net loss attributable to common shareholders was $21.7 million, or -$0.30 per share.
Non-GAAP adjusted EBITDA was a $192.6 million loss and non-GAAP net loss was $53.9 million. Cash, cash equivalents and restricted cash surged to $4.2 billion, mainly from maturities and sales of investment products, supporting a special cash dividend of $55.00 per share totaling $4.0 billion, of which $658 million remains payable pending litigation over 2018 PIPE shares. Management also concluded prior first-half 2024 unaudited results must be restated and should no longer be relied upon, reflecting corrections in legal and regulatory matters, revenue recognition estimates, credit losses, investment classifications and withholding tax.
Sinovac Biotech Ltd. filed this Form 6-K to correct a typographical error in Note 2 of its Form 20-F for the year ended December 31, 2024. The first-level subparagraphs in Note 2 on pages F-13 and F-14 were incorrectly numbered 1 through 10 and are now correctly designated A through J to match the related tables on pages F-15, F-16, F-18, F-19, F-21 and F-22. No changes are being made to the company’s financial statements or any other disclosures, and the annual report continues to speak as of the original April 30, 2026 filing date.
Sinovac Biotech Ltd. filed a delayed Form 20-F that restates its 2021–2023 financial statements and replaces prior audit opinions. The restatement follows a U.K. Privy Council ruling on the company’s rightful board and invalidation of a shareholder rights agreement, which led to the prior auditor resigning and its opinions being withdrawn. Zhonghua Certified Public Accountants has re-audited 2021–2024 under PCAOB standards, but management and the new auditor concluded internal control over financial reporting was ineffective as of 2024. Revenue has fallen sharply as COVID-19 vaccine sales collapsed and pricing pressure hit other key vaccines, while R&D spending remains very high. Despite this, the board approved a special cash dividend of $55.00 per common share in 2025, funded by large upstream dividends from Chinese subsidiaries, though cash relating to disputed 2018 PIPE shares is escrowed pending litigation. The filing also highlights extensive PRC regulatory, cash‑transfer, HFCAA and data/cybersecurity risks tied to the company’s China-based operations.
SINOVAC BIOTECH LTD director Li Jiaqiang filed an initial ownership report showing indirect control over 18,515,315 common shares of the company. These common shares, with par value $0.001 per share, are held through investment entities and related parties rather than directly.
The position consists of 6,812,855 common shares held by 1Globe Capital LLC, 6,000,000 common shares held by CDH Utopia Limited, and 5,702,460 common shares held by relatives or related parties. The filing notes that Li may be deemed the ultimate beneficial owner but disclaims beneficial ownership except to the extent of his pecuniary interest.
SINOVAC BIOTECH LTD executive Li Jing, VP of Quality and Production, has filed an initial insider ownership report. The filing shows direct ownership of 227,500 common shares, with no insider buy or sell transactions reported in this statement.